The treatment of multidrug-resistant tuberculosis in Turkey
- PMID: 11463011
- DOI: 10.1056/NEJM200107193450303
The treatment of multidrug-resistant tuberculosis in Turkey
Abstract
Background: We evaluated the results of treatment in 158 consecutive patients with multidrug-resistant tuberculosis who were treated at our center in Istanbul.
Methods: A total of 21 female patients and 137 male patients (age range, 15 to 68 years) received treatment for multidrug-resistant tuberculosis between March 1992 and October 1999. The patients had previously received a mean of 5.7 antituberculosis drugs and were infected with organisms that were resistant to a mean of 4.4 drugs. All patients were infected with organisms that were resistant to both isoniazid and rifampicin. The regimens we used were selected on the basis of previous treatment protocols and the results of susceptibility tests. All patients received at least three drugs thought to be active; the treatment was continued for at least 18 months after the conversion to a negative culture and for at least 24 months in the absence of first-line drugs.
Results: The mean number of drugs given during the study was 5.5 (range, 3 to 9). Surgical resection was performed in 36 patients. Adverse effects led to discontinuation of one or more drugs in 62 patients (39 percent). Cultures became negative in 150 patients (95 percent) after a mean of 1.9 months (range, 1 to 9). The overall success rate of treatment was 77 percent, with cures in 78 patients (49 percent) and probable cures in 43 (27 percent). Treatment failed in 13 patients (8 percent). Seven patients died (4 percent). Seventeen patients (11 percent) did not complete the treatment regimen. The patients with unsuccessful outcomes were older than those with successful outcomes (mean age, 42 years vs. 36 years; P=0.008), had received a larger number of drugs previously (median, six vs. five; P=0.048), were more likely to have been treated previously with ofloxacin (57 percent vs. 30 percent, P=0.004), and were less likely to have received ofloxacin as part of the study protocol (65 percent vs. 84 percent, P=0.018). Thirty-eight percent of the patients with unsuccessful outcomes were infected with organisms that were resistant to more than five drugs. In a step-down logistic-regression analysis, a successful outcome was independently associated with a younger age (P=0.013) and the absence of previous treatment with ofloxacin (P=0.005).
Conclusions: Most patients with multidrug-resistant tuberculosis can be cured with the use of appropriate, intensive treatment regimens.
Comment in
-
The major infectious diseases in the world--to treat or not to treat?N Engl J Med. 2001 Jul 19;345(3):208-10. doi: 10.1056/NEJM200107193450310. N Engl J Med. 2001. PMID: 11463018 No abstract available.
Similar articles
-
[Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].Kekkaku. 2003 Oct;78(10):611-7. Kekkaku. 2003. PMID: 14621568 Japanese.
-
Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.Int J Infect Dis. 2009 Mar;13(2):170-5. doi: 10.1016/j.ijid.2008.06.001. Epub 2008 Sep 2. Int J Infect Dis. 2009. PMID: 18768342
-
Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin.N Engl J Med. 1993 Feb 25;328(8):527-32. doi: 10.1056/NEJM199302253280802. N Engl J Med. 1993. PMID: 8426619 Clinical Trial.
-
A case series: initial outcome of persons with multidrug-resistant tuberculosis after treatment with the WHO standard retreatment regimen in Ho Chi Minh City, Vietnam.Int J Tuberc Lung Dis. 2001 Jun;5(6):575-8. Int J Tuberc Lung Dis. 2001. PMID: 11409587 Review.
-
[Therapy and prognosis of tuberculosis].Versicherungsmedizin. 1995 Dec 1;47(6):212-6. Versicherungsmedizin. 1995. PMID: 8571498 Review. German.
Cited by
-
Double Standards in Global Health: Medicine, Human Rights Law and Multidrug-Resistant TB Treatment Policy.Health Hum Rights. 2016 Jun;18(1):85-102. Health Hum Rights. 2016. PMID: 27781001 Free PMC article.
-
Imipenem for treatment of tuberculosis in mice and humans.Antimicrob Agents Chemother. 2005 Jul;49(7):2816-21. doi: 10.1128/AAC.49.7.2816-2821.2005. Antimicrob Agents Chemother. 2005. PMID: 15980354 Free PMC article.
-
Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines.PLoS Med. 2006 Sep;3(9):e352. doi: 10.1371/journal.pmed.0030352. PLoS Med. 2006. PMID: 16968123 Free PMC article.
-
The effect of surgery on the outcome of treatment for multidrug-resistant tuberculosis: a systematic review and meta-analysis.BMC Infect Dis. 2016 Jun 10;16:262. doi: 10.1186/s12879-016-1585-0. BMC Infect Dis. 2016. PMID: 27283524 Free PMC article.
-
Electronic laboratory system reduces errors in National Tuberculosis Program: a cluster randomized controlled trial.Int J Tuberc Lung Dis. 2010 Aug;14(8):1009-15. Int J Tuberc Lung Dis. 2010. PMID: 20626946 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources